In this article, we will look at Jim Cramer’s breakdown of 16 stocks, including pharma plays for rising oil. The host of Mad Money said on Wednesday that investors should prepare for rising uncertainty driven by higher oil prices and possible economic slowdown by shifting toward safer, dividend-paying pharmaceutical stocks.

They say when the facts change, we need to change our minds, and a whole lot has changed in the last three and a half weeks since the war with Iran got rolling. The price of oil has surged over 50% year-to-date… And we don’t know how long it’s going to stay elevated. Sooner or later, higher energy costs could do real damage to the rest of the economy. They’ve already made it a lot more difficult for the Federal Reserve to keep cutting interest rates…. All of that is weighing on the stock market, even if we managed some gains today. Long story short, there’s a tremendous amount of uncertainty in this market, and at times, coping with uncertainty carries a great deal of risk.

READ ALSO Buy, Sell, or Hold? Jim Cramer’s Latest 11 Stock Calls and Jim Cramer’s 10 Stock Calls and the Truth About Strong Consumer Spending Despite the Iran Conflict

Cramer turned to interpreting pharma stocks’ charts with the help of Bob Lang, whom he called risk-focused. He said Lang’s view is that investors should look for safer areas of the market to help protect capital, like pharmaceutical stocks. Cramer agreed with that and said Lang believes the economy may be entering the early stages of a slowdown.

Here’s the bottom line: The charts interpreted by Bob Lang suggest that it’s time to buy big, quality pharma names, okay, with bountiful dividends, and that means Pfizer, it means Merck, it means Bristol-Myers. These are textbook slowdown stocks, people. I’m not saying we’ll definitely have an oil shock that’s going to include a slowdown. I’m not as bearish as that. A lot depends on whether the Federal Reserve is willing to cut rates or not. But it’s a real possibility that we do get a slowdown, and I just showed you the kind of stocks that you want to buy.

Our Methodology

For this article, we compiled a list of 16 stocks that were discussed by Jim Cramer during the episode of Mad Money aired on March 25. We listed the stocks in the order that Cramer mentioned them.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

Jim Cramer Broke Down 16 Stocks, Including Pharma Plays for Rising Oil

16. Corteva, Inc. (NYSE:CTVA)

Jim Cramer reviewed Corteva, Inc. (NYSE:CTVA) while breaking down 16 stocks for a market facing higher energy costs and economic uncertainty. Toward the end of the lightning round, a caller asked for Cramer’s thoughts on the stock, and he said:

Okay, it’s an ag stock. We all know that crop protection and seeds are going to be very important this year because of what’s happened to the Gulf. I would continue to own the stock.

Corteva, Inc. (NYSE:CTVA) provides advanced seeds and trait technologies that are designed to help farmers improve crop yields and protect against weather and pests. The company also offers products like herbicides and insecticides. Hardman Johnston Global Equity Strategy stated the following regarding Corteva, Inc. (NYSE:CTVA) in its fourth quarter 2025 investor letter:

During the quarter we liquidated Corteva, Inc. (NYSE:CTVA), T-Mobile US, Inc. and Vertex Pharmaceuticals Inc. We exited our position in Corteva Inc. following management commentary around a potential separation of the Seeds and Crop Protection businesses, as we struggle to see a clear value-creation rationale given Corteva already trades at one of the richer multiples in the ag/chem peer group. While the Seeds business (c. two-thirds of profits) may command a premium multiple, this would likely be offset by a materially lower valuation for the Chemicals business, resulting in limited net value unlock. The separation narrative also raises strategic credibility concerns, as it appears inconsistent with prior management messaging around the complementary nature of Seeds and Chemicals on a single platform, as well as the long-term growth potential of higher-margin areas such as biologicals within Crop Protection. WSJ commentary suggesting a separation could be aimed at insulating the Seeds franchise from potential liabilities in the Chemicals business introduces additional uncertainty. At the same time, end-market fundamentals are becoming less supportive. U.S. corn acreage has risen to peak levels, increasing the risk of a sharp price correction if supply proves difficult to absorb, while soybean markets also face challenges given their reliance on exports and lower demand from China. Depressed farm economics over a prolonged period could pressure farmer spending on inputs. Taken together — elevated valuation, strategic uncertainty, and deteriorating agricultural fundamentals — we viewed the risk-reward as less compelling and chose to exit the position. We will be watching developments closely as the Seeds business is a truly unique franchise with high entry barriers and technological innovation.

15. BXP, Inc. (NYSE:BXP)

Jim Cramer reviewed BXP, Inc. (NYSE:BXP) while breaking down 16 stocks for a market facing higher energy costs and economic uncertainty. A caller asked if office REITs like BXP are “waiting on the Fed to lower interest rates or if there are structural issues with the sector.” Cramer replied:

I think there might be structural issues. More important, you’re only getting 5% yield for what I regard as being a risky situation. I mean, if you’re going to have risk, you got to get like six and a half. I do not, I would not touch that BXP. I just don’t want it. There, again, it’s too hard.

BXP, Inc. (NYSE:BXP) is a fully integrated real estate investment trust that develops, owns, and manages premier workplaces. While discussing relatively cheap S&P 500 stock during the episode aired on September 22, 2025, Cramer mentioned the stock and said:

Now, there’s only one single solitary real estate company that made our list, and that’s BXP. It’s a company, formerly known as Boston Properties, with a portfolio of mostly high-quality office properties in six major cities on the East and West Coast. Now, BXP trimmed its dividend earlier this month, which I thought, it was going to really kill it… But they did say they needed the cash to devote to growth projects, which is why I think the stock bounced right back. Even after that, it’s still got a 3.7% yield.

It is worth noting that, since the above comment was aired, the company’s share price has declined by over 30%.